Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept

Clinical Infectious Diseases

Volumn 52, Issue 5, 2011, Pages

  Ramien, Michele L ^a   Wong, Alexander ^b   Keystone, Jay S ^c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; ETANERCEPT; OFLOXACIN; PREDNISONE; RIFAMPICIN; THALIDOMIDE;

ADULT; ARTICLE; CASE REPORT; CUBITAL TUNNEL SYNDROME; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; EAR DISEASE; ERYTHEMA; ERYTHEMA NODOSUM LEPROSUM; FACE DISORDER; FACE RASH; FEMALE; FEVER; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; LEPROMATOUS LEPROSY; LYMPHADENOPATHY; MALAISE; NEURITIS; PRIORITY JOURNAL; SKIN DEFECT; SMEAR;

ADULT; ERYTHEMA NODOSUM; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; LEPROSY, LEPROMATOUS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951821206     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq213     Document Type: Article

References (18)

1. Boggild AK, Keystone JS, Kain KC. Leprosy: a primer for Canadian physicians. CMAJ 2004;170:71-8. (Pubitemid 38125464)
2. World Health Organization (WHO). WHO weekly epidemiology record: global leprosy situation, beginning of 2008. 2008;83:293-300.
3. Cuevas J, Rodriguez-Peralto JL, Carrillo R, Contreras F. Erythema nodosum leprosum: reactional leprosy. Semin Cutan Med Surg 2007;26:126-30. (Pubitemid 46829964)
4. Van Veen NH, Lockwood DN, van Brakel WH, Ramirez J Jr., Richardus JH. Interventions for erythema nodosum leprosum. Cochrane Database Syst Rev 2009; CD006949.
5. Wemambu SN, Turk JL, Waters MF, Rees RJ. Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon. Lancet 1969;2:933-5.
6. Ridley MJ, Ridley DS. The immunopathology of erythema nodosum leprosum: the role of extravascular complexes. Lepr Rev 1983;54:95-107. (Pubitemid 13046647)
7. Scollard DM, Bhoopat L, Kestens L, Vanham G, Douglas JT, Moad J. Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Clin Immunol Immunopathol. 1992;63:230-6.
8. Kahawita IP, Lockwood DN. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg 2008;102:329-37.
9. Faber WR, Jensema AJ, Goldschmidt WF. Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med 2006;355:739.
10. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5. (Pubitemid 38608568)
11. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70. (Pubitemid 36118917)
12. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005;41: S199-203. (Pubitemid 41022091)
13. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9.
14. Kim JY, Park JN, Lee JG, et al. The use of etanercept in a patient with disseminated tuberculosis. Rheumatol Int 2009;29:1377-80.
15. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumornecrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006;194:486-92. (Pubitemid 44162660)
16. Tubach F, Salmon D, Ravaud P, et al; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884-94.
17. Haslett PA, Roche P, Butlin CR, et al. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J Infect Dis 2005;192:2045-53. (Pubitemid 41779200)
18. Villahermosa LG, Fajardo TT Jr., Abalos RM, et al. A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. Am J Trop Med Hyg 2005;72:518-26. (Pubitemid 41278818)